Rifampin

C. diff Risk

Low

Oral Bioavailability

Excellent

Approximate Cost

IV:$$$
PO:$

Dosing

Adult

Mycobacterial Infections
600 mg IV/PO Q24H

Endocarditis
300 mg IV/PO Q8H

Prosthetic Device Infections
450 mg IV/PO Q12H

Renal

No dose adjustment

Hepatic

No dose adjustment

General Information

Common Usage

Prosthetic infections due to Staph aureus (in combination with other agents), Mycobacterial infections, Brucellosis

Drug Monitoring

Laboratory

  •  LFTs at baseline and periodically

Clinical

  • Multiple drug-drug interactions

Adverse Effects

  •  Abnormal liver enzymes

  •  Skin rash

  • GI intolerance

Major Interactions

Many via CYP interactions - review specific patient medications

Additional Information

May turn bodily secretions reddish-orange; caution in contact lens wearers

Never use as monotherapy except in latent TB